Janssen Search
Search results
Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
Mar 26, 2024 United States FNAIT is a rare disease that occurs when a pregnant person’s immune system attacks fetal platelets, resulting in the risk of internal bleeding, which can be life threatening to the fetus or newborn The Phase 3 FREESIA program is ...
ACR/ARHP Annual Meeting
The 2020 ACR/ARHP Annual Meeting will take place November 6–11 in Washington D.C. The American College of Rheumatology’s Annual Meeting is the largest rheumatology meeting in the world and the premier educational event for physicians, healthcare ...
World TB Day
World Tuberculosis Day is a worldwide event that aims to raise public awareness about the devastating health, social and economic consequences of tuberculosis (TB) and to step up efforts to end the global TB epidemic. The date marks the day in 1882 when ...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
May 03, 2024 New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG) – unresponsive high-risk non – muscle ...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
Jun 03, 2024 73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy 1 CHICAGO (June 3, 2024) – Johnson & Johnson ...
World PH Day
Every year on May 5, pulmonary hypertension organizations and groups around the world participate in World Pulmonary Hypertension Day activities to raise awareness of this frequently misdiagnosed disease and celebrate the lives of people living with PH. ...
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Jun 06, 2023 United States Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival (PFS) CARTITUDE-4 is the first randomized Phase 3 study investigating the ...
Update on Janssen’s BACE Inhibitor Program
Update on Janssen’s BACE Inhibitor Program May 18, 2018 Titusville, NJ, May 17, 2018- At Janssen, the safety and well-being of people who participate in our clinical trials are of utmost importance to us. For the past several years, we have been studying ...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Jun 20, 2024 TREMFYA® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. (June 20, 2024) /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 ...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma
Dec 12, 2023 United States DARZALEX FASPRO ®-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen First presentation of data from Phase 3 PERSEUS study highlighted ...